



Republic of the Philippines  
**PHILIPPINE HEALTH INSURANCE CORPORATION**

Citystate Centre, 709 Shaw Boulevard, Pasig City  
 Call Center (02) 441-7442 Trunkline (02) 441-7444  
[www.philhealth.gov.ph](http://www.philhealth.gov.ph)



**PHILHEALTH CIRCULAR**

No. 018-0009

**FOR : ALL ACCREDITED HEALTH CARE PROVIDERS AND OTHERS CONCERNED**

**SUBJECT : Use of Restricted Antimicrobials in PhilHealth-Accredited Health Care Institutions in Accordance with the Antimicrobial Resistance Surveillance Program (ARSP)**

**I. RATIONALE**

Antimicrobial resistance is currently a public health problem in many countries. One major driver in the emergence of drug-resistance is the “selective pressure” brought about by the irrational and irresponsible use of antimicrobials by health care professionals. In an effort to ensure that only reliable quality microbiology laboratory test results are used to guide rational antimicrobial use, PhilHealth partnered with the **Antimicrobial Resistance Surveillance Reference Laboratory** for antimicrobial resistance (DO 393-E s 2000) for the implementation of a quality assurance scheme that allowed PhilHealth reimbursements for select restricted Philippine National Drug Formulary (PNDF) antibiotics only for hospitals with ARSP accredited laboratories.

To ensure that restricted antimicrobials are used rationally, DOH Administrative Order No. 2016-0034: **The New Implementing Guidelines of the Philippine National Formulary System (PNFS)** provided guidelines which include new requirements for the use of restricted antimicrobials in the latest PNDP for hospitals.

**II. OBJECTIVES**

This circular aims to adopt and implement the DOH AO No. 2016-0034 Item VII.B.6 on the mandatory use of drugs in the Philippine National Formulary, specifically on the provisions on procurement of restricted antimicrobials in health facilities. This aligns PhilHealth claims reimbursement policy with the DOH AO to assure favorable health outcomes to members by preventing the irrational use of the restricted antimicrobials.

**III. SCOPE**

All accredited infirmaries/primary care facilities and hospitals that utilize restricted antimicrobials.

**DEFINITION OF TERMS**

- A. Antimicrobial Resistance (AMR) – is the ability of organisms that cause disease to withstand attack by antimicrobials.
- B. Antimicrobial Resistance Surveillance Program (ARSP) – is a program of the DOH which aims to provide critical inputs to the DOH’s effort to promote rational drug use


MASTER COPY  
 Date: 3/27/18  
 DC: nys

by determining the status and trends of antimicrobial resistance of selected bacteria to specific antibiotics.

- C. Tertiary clinical laboratory – A clinical laboratory, regardless of its classification by ownership, function, and institutional character which provides minimum service capabilities for the following: routine and special hematology including coagulation procedures, qualitative and quantitative platelet determination, routine urinalysis and fecalysis, routine clinical and special chemistry, cross matching\*, KOH\*, blood typing\*, immunology, and microbiology-culture and sensitivity. (\* for hospital based only)
- D. AMS program – Antimicrobial Stewardship program is the program of the DOH tasked with concerted implementation of systematic, multi-disciplinary, multi-pronged interventions in both public and private hospitals in the Philippines to improve appropriate use of antimicrobials, which is essential for preventing the emergence and spread of AMR.
- E. Adverse Monitoring Findings – performance of health care providers that show deviations from PhilHealth policies and treatment protocols which may result to abuse or compromise the National Health Insurance Program (NHIP). These are identified during conduct of the monitoring activities prescribed by the Corporation. (source: PhilHealth Circular No. 2016-0026)

## V. GENERAL GUIDELINES

- A. Restricted antimicrobials shall only be utilized by institutions with tertiary clinical laboratories which have ARSP laboratory accreditation.
- B. The restricted antimicrobials as stated in the Philippine National Formulary 8<sup>th</sup> edition 2017 are listed in ANNEX A.
- C. All future DOH issuances identifying restricted antimicrobials shall automatically be adopted by PhilHealth. ANNEX A shall be updated accordingly through an Advisory posted in the PhilHealth website.
- D. Transition period for hospitals to attain ARSP Laboratory Accreditation as a requirement for utilization of restricted antimicrobials:
  - 1. Compliance period until June 2019 will be implemented. The list of hospitals with provisional ARSP accreditation shall be provided by RITM – DOH to PhilHealth and shall be regularly updated. Use of restricted antimicrobials by facilities with no ARSP accredited laboratory shall not be an “adverse monitoring finding” during post-audit or monitoring activities if:
    - a. They will present either of the following documents issued by Antimicrobial Resistance Surveillance Reference Laboratory (ARSL) of Research Institute for Tropical Medicine: “**Acknowledgement letter for Phase 1 ARSP Accreditation**” (ANNEX-B) or the **Notification for compliance to Phase 2 ARSP accreditation (ANNEX-C)** containing the list of requirements for compliance identified during inspection; AND
    - b. Relevant cultures are taken from patients for whom restricted antimicrobials are used with the results attached to medical charts and should be readily available during PhilHealth’s validation or post-audit activities.
  - 2. By July 2019, as imposed by the DOH issued Administrative Order No. 2016-0034 “The New Implementing Guidelines of the Philippine National Formulary System



(PNFS)", aside from the requirement for the microbiology laboratory to be ARSP accredited, all secondary and tertiary hospitals should have any of the following:

- a. A DOH AMS trained chairperson of either the hospital's Infection Control Committee (ICC) or Antimicrobial Stewardship (AMS) Committee. The hospital shall provide a copy of the Certificate of Training on AMS of current personnel to their respective PhilHealth Regional Office (PRO); or
  - b. A board-certified infectious disease specialist that shall authorize the use of the restricted antimicrobials per patient.
  - c. For hospitals which will not attain ARSP accreditation after July 2019, may outsource with an ARSP Accredited Laboratory. A copy of a valid Memorandum of Agreement (MOA) shall be provided to the respective PRO.
- E. Inappropriate or unauthorized use of restricted antimicrobials shall not result in denial of a claim but shall be considered as an "Adverse Monitoring Findings" during claims post-audit or any monitoring activity wherein cumulated offenses shall have bearing on a provider's accreditation renewal.
- F. For queries and accreditation applications on ARSP, the HCI may refer to the details below:

**Antimicrobial Resistance Surveillance Program .**


Research Institute for Tropical Medicine - Department of Health  
9002 Research Drive, Filinvest Corporate City, Alabang, Muntinlupa City 1781  
Direct Line: (02) 809-9763 Trunk Line: (02) 807-2631 to 32 loc. 243  
Email: [secretariat@arsp.com.ph](mailto:secretariat@arsp.com.ph)  
Website: [www.arsp.com.ph](http://www.arsp.com.ph)

**VI. REPEALING CLAUSE**


PhilHealth Circular Nos. 15 s.2006, 18 s.2006, 4 s.2007, 16 s.2007 and any other previous issuances, circulars, and directives that are inconsistent with any of the provisions of this Circular, are hereby amended, modified or repealed accordingly.

**VII. EFFECTIVITY**

This Circular shall take effect after fifteen days following its publication in any newspaper of general circulation and shall be deposited thereafter with the National Administrative Register at the University of the Philippines Law Center.

  
DR. CELESTINA MA. JUDE P. DE LA SERNA  
Interim/OIC President and CEO

Date signed: 2/27/18



SUBJECT: Use of Restricted Antimicrobials in PhilHealth-Accredited Health Care Institutions in Accordance with the Antimicrobial Resistance Surveillance Program (ARSP)

**ANNEX A**

The following are the restricted antimicrobials as stated in the Philippine National Formulary 8th edition 2017:

	<b>Medicine</b>	<b>Dosage Form/Strength</b>
1	Cefepime	500 mg, 1 g and 2 g vial (as hydrochloride)
2	Ertapenem	1 g powder, vial (as sodium salt)
3	Meropenem	500 mg and 1 g powder, vial (as trihydrate)
4	Vancomycin	500 mg and 1 g vial (as hydrochloride)
5	Amphotericin B	50 mg and 100 mg vial (IV infusion) (as cholesteryl complex, colloidal suspension) (lipid complex) 50 mg lyophilized powder, vial (IV infusion) (as deoxycholate) (non-lipid)
6	Voriconazole	200 mg lyophilized powder for solution for IV infusion, 30 ml vial
7	Colistin	2000000 IU lyophilized powder for injection (IV infusion)
8	Micafungin	50 mg lyophilized powder for infusion (IV)
9	Aztreonam	1 g powder for injection
10	Linezolid	600 mg tablet/film-coated tablet 2 mg/ml (600 mg/300mL0, solution for infusion (IV)

MASTER COPY  
DC: *mys* Date: *3/27/18*



# Research Institute for Tropical Medicine - Department of Health

9002 Research Drive, Filinvest Corporate City, Alabang, Muntinlupa City, 1781 Philippines  
Tel Nos.: (632) 809-7599 / 807-2631/32/37 • Fax: (632) 842-2245 • Website: www.ritm.gov.ph



## ANNEX B

### Acknowledgement letter for Phase 1 ARSP Accreditation

Date

\_\_\_\_\_  
\_\_\_\_\_  
\_\_\_\_\_

Dear Dr. \_\_\_\_\_,

Please be informed that your application for accreditation to the Department of Health - Antimicrobial Resistance Surveillance Program (DOH-ASRP) has been accepted. Your laboratory is herewith acknowledged as among the participants for the accreditation cycle \_\_\_\_\_ Aug (year) to July (year)).


Please expect to receive proficiency test samples by \_\_\_\_\_. Please submit the results of your testing of the proficiency test samples on or before the deadline set in the letter accompanying the test samples. Failure to submit the results on time will mean removal of your laboratory from the list of participants for the above mentioned accreditation cycle and the possibility of being issued an adverse observation during postaudit/monitoring activity by PhilHealth.

The Antimicrobial Resistance Surveillance Reference Laboratory (ARSRL) at the Research Institute for Tropical Medicine is glad to partner with your hospital in ensuring provision of quality laboratory data to clinicians for selecting the most effective and appropriate antibiotic regimens for treatment of infectious diseases at the lowest cost to our patients.

For further queries on your application, you can email the ARSP secretariat at [arsp.secretariat@yahoo.com](mailto:arsp.secretariat@yahoo.com) or call at (02) 809-9763.

Yours truly,

MASTER COPY  
DC: MS Date: 3/27/18





**ANNEX C**

**Notification for Compliance to Phase 2 ARSP Accreditation**

Date

\_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_

Dear Dr. \_\_\_\_\_

Greetings from ARSRL- RITM!

With regards to your on-going application for accreditation with the Antimicrobial Resistance Surveillance Program, we would like to inform your good office of the following items for compliance:

Items for compliance	Remarks
1.	
2.	

The said requirements are crucial in providing evidence in the capacity of your laboratory in generating quality data. Kindly submit/comply with the said requirements on or before \_\_\_\_\_ to avoid being issued an adverse observation during postaudit/monitoring by PhilHealth

For further information on the above listing, you can email the ARSP secretariat at [arsp.secretariat@yahoo.com](mailto:arsp.secretariat@yahoo.com) or call at (02) 809-9763.

Yours truly,

ARSP Program chair

MASTER COPY  
 DC: *Nys* Date: *3/27/18*

